Home
    Disclaimer
    N-Methyl-Cyclazodone molecular structure

    N-Methyl-Cyclazodone Stats & Data

    Nmc Ld 4202
    Chemical Class Amphetamine
    Psychoactive Class Stimulant
    Half-Life Estimated 6 – 10 h (no formal human PK study; inferred from user reports)

    Effect Profile

    Curated
    Stimulant 5.6

    Strong anxiety/jitters with moderate stimulation and euphoria, mild focus

    Stimulation / Energy×3
    7
    Euphoria / Mood Lift×2
    7
    Focus / Productivity×2
    5
    Anxiety / Jitters×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Estimated 6 – 10 h (no formal human PK study; inferred from user reports)
    Addiction Potential
    Moderate: psychological dependence similar to other prescription stimulants; community reports describe compulsive redosing and next‑day anergia when high doses or frequent use are employed.

    Tolerance Decay

    Full tolerance 5d Half tolerance 4d Baseline ~18d

    Estimates above reflect community patterns for stimulant tolerance accrual and decay and the similarity between NMC and cyclazodone; no human pharmacology studies define exact rates. Frequent use (>2x/week) appears to blunt mood/drive and increase side effects. Data quality: anecdotal.

    Cross-Tolerances

    Cyclazodone
    70% ●○○
    Pemoline derivatives
    50% ●○○
    Amphetamine-class stimulants
    30% ●○○

    Harm Reduction

    drugs.wiki

    Human data are scarce; pemoline (the parent scaffold) was withdrawn in the U.S. after association with rare but severe hepatic failure, so NMC should be treated as potentially hepatotoxic until proven otherwise. Consider baseline and periodic liver function tests if using repeatedly or at higher doses. Prolonged wakefulness can obscure sleep debt, and appetite suppression may lead to malnutrition. Insomnia is commonly reported after larger doses or late dosing; several experienced users advise avoiding dosing after morning hours. Community reports flag nausea and a “drained”/serotonin‑depletion‑like feeling at higher cumulative doses, consistent with some serotonergic activity; avoid frequent redosing and keep use infrequent. A 5‑day self‑medication episode totaling ~5 g led to hospital evaluation for palpitations/agitation per a widely shared warning; this illustrates overdose potential from misjudged potency—start low, avoid solutions with unknown concentration, and do not use daily. As with other stimulants, combinations with MAOIs are high‑risk (hypertensive crisis/serotonin toxicity); stimulant + alcohol or high caffeine increases cardiac strain and dehydration risk; tramadol raises seizure risk when combined with stimulants—avoid. If any signs of liver injury (e.g., dark urine, right‑upper‑quadrant pain, jaundice) emerge, stop immediately and seek medical care.

    ← Back to N-Methyl-Cyclazodone